Bridges C B, Winquist A G, Fukuda K, Cox N J, Singleton J A, Strikas R A
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, USA.
MMWR Recomm Rep. 2000 Apr 14;49(RR-3):1-38; quiz CE1-7.
This report updates 1999 recommendations by the Advisory Committee on Immunization Practices (ACIP) on the use of influenza vaccine and antiviral agents (MMWR 1999;48[No. RR-4]: 1-29). These recommendations include five principal changes: a) the age for universal vaccination has been lowered to 50 years from 65 years; b) scheduling of large, organized vaccination campaigns after mid-October may be considered because the availability of vaccine in any location cannot be assured consistently in the early fall; c) 2000-2001 trivalent vaccine virus strains are A/Moscow/10/99 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Beijing/184/93-like strains; d) information on neuraminidase-inhibitor antiviral drugs has been added; and e) a list of other influenza-related infection control documents for special populations has been added. This report and other information on influenza can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC at <http://www. cdc.gov/ncidod/diseases/flu/fluvirus.htm>.
本报告更新了免疫实践咨询委员会（ACIP）1999年关于流感疫苗和抗病毒药物使用的建议（《发病率与死亡率周报》1999年；48[第RR - 4号]：1 - 29）。这些建议包括五项主要变化：a）普遍接种疫苗的年龄已从65岁降至50岁；b）可考虑在10月中旬之后安排大规模、有组织的疫苗接种活动，因为在初秋无法始终确保任何地点都有疫苗供应；c）2000 - 2001年三价疫苗病毒株为A/莫斯科/10/99（H3N2）类似株、A/新喀里多尼亚/20/99（H1N1）类似株和B/北京/184/93类似株；d）增加了关于神经氨酸酶抑制剂抗病毒药物的信息；e）增加了一份针对特殊人群的其他流感相关感染控制文件清单。本报告及其他关于流感的信息可在疾病控制与预防中心（CDC）国家传染病中心病毒和立克次体疾病司流感处的网站http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm上获取。
